藥品產業利用PLM的資訊流合理化

本報告已在2011年07月19日停止出版。

簡介

目錄

Abstract

Overview

Introduction

This report offers insight into PLM in the pharmaceutical industry, bringing together all briefs published for this theme. The report covers market trends, technological components which Datamonitor believes are key for this sector, and four critical vendor attributes used by pharmaceutical companies to select a PLM vendor.

Scope

• From Idea to Market: Product Lifecycle Management in the Pharmaceutical Industry (Market Focus)
• Optimizing PLM Technology for the Pharmaceutical Industry (Technology Focus)
• Managing Process Complexity in the Pharmaceutical Industry with PLM (Strategy Focus)
• Pharmaceutical PLM Forecast in North America, Europe and APAC 2006-2012 (Databooks)

Report Highlights

• Pharmaceutical product lifecycle management technology is gaining momentum
• PLM addresses key business challenges facing the pharmaceutical industry
• PLM is successful when treated as an enterprise, strategic initiative

Reasons to Purchase

• Gain valuable industry insight into the market drivers and inhibitors for product lifecycle management solutions in the life sciences market
• Align your go-to-market strategy with both the business and technology needs of the pharmaceutical industry
• Quantify the current and projected market opportunity for PLM in the pharmaceutical industry in North America, Western Europe, China and Japan.

Table of Contents

• Overview
  • Catalyst
  • Summary
  • Methodology
• Executive Summary
  • Introduction
  • From Idea to Market: Product Lifecycle Management in the Pharmaceutical Industry (Market Focus)
  • Optimizing PLM Technology for the Pharmaceutical Industry (Technology Focus)
  • Managing Process Complexity with PLM (Strategy Focus)
  • Pharmaceutical Product Lifecycle Management Forecast in North America 2006-2012 (Databook)
  • Pharmaceutical Product Lifecycle Management Forecast in Western Europe 2006-2012
  • Pharmaceutical Product Lifecycle Management Forecast in APAC 2006-2012
• Table of Contents
• Table of figures
• Table of tables
• From Idea to Market: Product Lifecycle Management in the Pharmaceutical Industry (market focus)
  • Summary
  • Product lifecycle management will transform the drug development lifecycle process
    • The nature of a drug' s lifecycle necessitates a PLM strategy
  • PLM addresses key business challenges facing the pharmaceutical industry
    • A greater focus on decreasing time to market is driving adoption of PLM
    • Harmonizing product portfolios from M&A activities sets the stage for PLM
    • Reducing the challenges and cost associated with regulatory compliance
    • The nature of the pharmaceutical drug pipeline is changing
      • Complexity of pharmaceutical products is increasing
      • The end of the Blockbuster era signifies more candidates in the pipeline
  • Successful PLM for the pharmaceutical industry prevails over several constraining factors
    • Repurposing software from other industries makes the pharmaceutical industry suspicious
    • The traditional autonomous-business-unit mentality inhibits adoption of PLM
    • PLM does not mean an antidote to new product development
• ACTIONS
  • Articulate strategic business benefits of your PLM investment decisions
  • Take a holistic approach to PLM
  • Understand how PLM changes the lifecycle processes of a pharmaceutical product
• Optimizing PLM Technology for the Pharmaceutical Industry (technology Focus)
  • Summary
  • PLM technology should align to the pharmaceutical industry' s business challenges
    • Digitizing research information earlier in the product lifecycle is an essential first step towards PLM
      • The electronic notebook offers an entry point to a connected and global product management system
    • PLM links disparate technologies offering a single point of truth for each drug in development
    • Alleviating risks of non-compliance is a key application for PLM in the pharmaceutical industry
  • Six technology features reflect how PLM technology is aligned to the industry
    • Scalability places SOA at the center of a PLM solution
    • A quality-by-design feature facilitates compliance
    • PLM must integrate with ERP solutions
    • A web-enabled PLM solution matches the global nature of most pharmaceutical organizations
    • A easy-to-configure user interface drives adoption amongst both scientists and engineers
    • The industry is most comfortable with non-hosted solutions
  • PLM technology adoption differs across geographies
    • Japan and China will experience the fastest growth in PLM
• ACTIONS
  • Offer technology features that speak to the customer' s business goals
  • Make PLM a core part of the customer' s every day life
  • Consider geography as a criterion for prioritizing your target market
• Managing Process Complexity with PLM (Strategy Focus)
  • Summary
  • Pharmaceutical product lifecycle management technology is gaining momentum
    • A variety of challenges is fueling PLM adoption in the pharmaceutical industry
    • Cultural and technological barriers have inhibited wider adoption of PLM in the pharmaceutical market
    • PLM in the pharmaceutical industry is poised for strong growth and vendors have an important role to play
  • PLM in the life sciences should map to business processes, managing process complexity
    • Pharmaceutical companies produce what they discover, not what they invent
    • The pharmaceutical sector looks for PLM that can manage process complexity
  • PLM is successful when handled as an enterprise, strategic initiative
    • As part of a company' s product development business strategy, PLM is discussed among executives
    • Collaboration, through enterprise PLM, breaks down individual silos
    • Reducing drug development costs is a major strategic goal for implementing enterprise PLM
    • The benefits of an enterprise-wide PLM solution do come with risks
    • A phased implementation approach is most likely for pharmaceutical organizations
  • Partnering with a technology vendor may be a necessary PLM strategy
    • A long-term commitment to the project indicates a willingness to share risk
    • Innovative and flexible vendors will attract most business
    • Implementation efficiency is an important vendor characteristic
    • Track record of success reflects on a vendor' s reliability and trustworthiness
• ACTIONS
  • PLM must support executive-level decisions
  • Have a long-term vision but establish short-term milestones
  • Look beyond point solutions for a strategic approach to PLM
• Pharmaceutical Product Lifecycle Management Forecast in North America 2006-2012 (Databook)
  • Summary
• iNTRODUCTION
  • Definitions
  • Total PLM spending in the pharmaceutical industry in North America
  • Total pharmaceutical PLM spending in North America by technology segment
  • US PLM spending in the pharmaceutical industry 2006-2012
  • Canada PLM spending in the pharmaceutical industry 2006-2012
  • Total North America PLM spending in the pharmaceutical industry by sector
  • Global PLM spending by geographic region
• Pharmaceutical Product Lifecycle Management Forecast in Western Europe 2006-2012 (Databook)
  • Summary
• iNTRODUCTION
  • Definitions
  • Total PLM spending in the pharmaceutical industry in Western Europe
  • Total pharmaceutical PLM spending in Western Europe by technology segment
  • Total pharmaceutical PLM spending in Western Europe by sector
  • France PLM spending in the pharmaceutical industry 2006-2012
  • Germany PLM spending in the pharmaceutical industry 2006-2012
  • UK PLM spending in the pharmaceutical industry 2006-2012
  • Italy PLM spending in the pharmaceutical industry 2006-2012
  • Spain PLM spending in the pharmaceutical industry 2006-2012
  • Switzerland PLM spending in the pharmaceutical industry 2006-2012
  • Global PLM spending by geographic region
• Pharmaceutical Product Lifecycle Management Forecast in APAC 2006-2012 (Databook)
  • Summary
• iNTRODUCTION
  • Definitions
  • Global PLM spending by geographic region
  • Total PLM spending in the pharmaceutical industry in APAC
  • China PLM spending in the pharmaceutical industry 2006-2012
  • Japan PLM spending in the pharmaceutical industry 2006-2012
  • Total APAC PLM spending in the pharmaceutical industry by sector
• APPENDIX
  • Definitions
  • Abbreviations
  • Methodology
  • Further reading
  • Ask the analyst
  • Datamonitor consulting
  • Disclaimer
  • List of Tables
    • Table 1: Total PLM spending in the pharmaceutical industry in North America
    • Table 2: Total pharmaceutical PLM spending in North America by technology segment
    • Table 3: US PLM spending in the pharmaceutical industry 2006-2012
    • Table 4: Canada PLM spending in the pharmaceutical industry 2006-2012
    • Table 5: Total North America PLM spending in the pharmaceutical industry by sector
    • Table 6: Global PLM spending by geographic region
    • Table 7: Total PLM spending in the pharmaceutical industry in Western Europe
    • Table 8: Total pharmaceutical PLM spending in Western Europe by technology segment
    • Table 9: Total pharmaceutical PLM spending in Western Europe by sector 2006-2012
    • Table 10: France PLM spending in the pharmaceutical industry 2006-2012
    • Table 11: Germany PLM spending in the pharmaceutical industry 2006-2012
    • Table 12: UK PLM spending in the pharmaceutical industry 2006-2012
    • Table 13: Italy PLM spending in the pharmaceutical industry 2006-2012
    • Table 14: Spain PLM spending in the pharmaceutical industry 2006-2012
    • Table 15: Switzerland PLM spending in the pharmaceutical industry 2006-2012
    • Table 16: Global PLM spending by geographic region
    • Table 17: Global PLM spending by geographic region
    • Table 18: Total PLM spending in the pharmaceutical industry in APAC
    • Table 19: China spending in the pharmaceutical industry 2006-2012
    • Table 20: Japan PLM spending in the pharmaceutical industry 2006-2012
    • Table 21: Total North America PLM spending in the pharmaceutical industry by sector
  • List of Figures
    • Figure 1: The pharmaceutical product lifecycle is highly regulated, more complex and longer than other industries
    • Figure 2: Drug discovery licensing dependence of the top 10 pharmaceutical companies
    • Figure 3: PLM spending in the pharmaceutical market is set for strong growth over the next five years
    • Figure 4: PLM in relation to ERP, CRM and BI
    • Figure 5: PLM software must evolve to configurable packages to better meet the pharmaceutical industry' s needs
    • Figure 6: Global PLM spending by geographic region
    • Figure 7: In the pharmaceutical industry, complexity in the process defines the product
    • Figure 8: Making a value proposition for PLM as a strategy in the pharmaceutical product lifecycle
    • Figure 9: As the Big Pharma begins to face its information management needs, enterprise PLM investments will grow
    • Figure 10: Examples of "must-have" and "nice-to-have" criteria pharmaceutical companies use for selecting a PLM vendor as potential partner
    • Figure 11: Total PLM spending in the pharmaceutical industry in North America
    • Figure 12: Total pharmaceutical PLM spending in North America by technology segment
    • Figure 13: US PLM spending in the pharmaceutical industry 2006-2012
    • Figure 14: Canada PLM spending in the pharmaceutical industry 2006-2012
    • Figure 15: Total North America PLM spending in the pharmaceutical industry by sector
    • Figure 16: Global PLM spending by geographic region
    • Figure 17: Total PLM spending in the pharmaceutical industry in Western Europe
    • Figure 18: Total pharmaceutical PLM spending in Western Europe by technology segment
    • Figure 19: Total pharmaceutical PLM spending in Western Europe by sector 2006-2012
    • Figure 20: France PLM spending in the pharmaceutical industry 2006-2012
    • Figure 21: Germany PLM spending in the pharmaceutical industry 2006-2012
    • Figure 22: UK PLM spending in the pharmaceutical industry 2006-2012
    • Figure 23: Italy PLM spending in the pharmaceutical industry 2006-2012
    • Figure 24: Spain PLM spending in the pharmaceutical industry 2006-2012
    • Figure 25: Switzerland PLM spending in the pharmaceutical industry 2006-2012
    • Figure 26: Global PLM spending by geographic region
    • Figure 27: Global PLM spending by geographic region
    • Figure 28: Total PLM spending in the pharmaceutical industry in APAC
    • Figure 29: China spending in the pharmaceutical industry 2006-2012
    • Figure 30: Japan PLM spending in the pharmaceutical industry 2006-2012
    • Figure 31: Total APAC PLM spending in the pharmaceutical industry by sector

相關商品

製藥企業相關市場調查報告書

生物標記相關合作契約
Biomarker Partnering Terms and Agreements
價格 : US $ 2695
出版日期 : 2012年02月

最佳實務：轉譯研究-朝向產業轉換前進
Best Practices: Translational Research - Positive Steps on the Path to Industry Transformation
價格 : US $ 4500
出版日期 : 2011年12月

製藥產業的合作，授權，投資，收購與合併交易趨勢:2011年12月
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - December 2011
價格 : US $ 1000
出版日期 : 2011年12月

Datamonitor發行的製藥相關市場調查報告書

研究開發趨勢:心房纖維顫動患者預防中風用的抗凝血劑─即將上市的重量級新產品將留下永不消失的足跡

R&D Trends: Anticoagulants for stroke prevention in atrial fibrillation - Upcoming heavy hitters leave a permanent mark

價格 : US $ 3800

出版日期 : 2011年11月

Novartis AG:企業概要

Novartis AG: PharmaVitae Report

價格 : US $ 5700

出版日期 : 2011年11月

Novo Nordisk A/S:企業概要

Novo Nordisk A/S: PharmaVitae Profile

價格 : US $ 5700

出版日期 : 2011年11月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!